What changed from existing technology?
This study found that in some stomach cancers, immune cell structures called tertiary lymphoid structures (TLS) are more common in tumors that don't respond to treatment. These structures may help the cancer avoid the immune system.
This is the first study to show that TLS in the muscularis propria of gastric cancer are associated with resistance to immunotherapy and may contribute to immunosuppression.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
uorescence to analyze surgical tumor specimens from 71 patients with gastric cancer (GC) after treatment with neoadjuvant anti-PD-1 therapy, chemotherapy, and
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding may help identify patients who are less likely to respond to immunotherapy and could guide treatment decisions.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.